About Captor

 

Captor Therapeutics is an innovative biopharmaceutical group specializing in the development of drugs based on Targeted Protein Degradation (“TPD”) and a European leader of this rapidly evolving technology.

The Company's strategy is based on building a competitive advantage by completely focusing on the exploitation of our TPD drug discovery platform and the continuous maintenance and commercialisation of a high value pipeline composed of drug candidates with the potential to treat severe diseases for which there are no satisfactory treatment. On 19 April 2021 Captor Therapeutics S.A. debuted on the Warsaw Stock Exchange, becoming the first European public company fully dedicated to the TPD technology. Captor is located in Basel, Switzerland and Wroclaw, Poland.